Marinus Pharmaceuticals Sees FY23 Ztalmy (Ganaxolone) Revenues Of $19.5M-$19.7M, With Q4 Ztalmy Revenues Of $6.5M-$6.7M
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals forecasts FY23 revenues for Ztalmy (Ganaxolone) to be between $19.5M-$19.7M, with Q4 revenues estimated at $6.5M-$6.7M.
January 04, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals expects FY23 revenues from Ztalmy to reach $19.5M-$19.7M, with Q4 contributing $6.5M-$6.7M to this total.
The revenue forecast for Ztalmy is a critical financial metric that directly reflects on Marinus Pharmaceuticals' performance. Positive revenue guidance often leads to increased investor confidence and can positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100